Brandon May

The use of biologics for the treatment of psoriasis was the focus of compelling research presented at AAD 2023.

Investigators presented data at AAD 2023 from their study in which they evaluated outcomes following in-person and teledermatology visits for high-risk melanoma assessment.

A retrospective cohort study evaluated a claims database to compare the incidence of melanoma, squamous cell carcinoma, and basal cell carcinoma among insured adult patients with and without atopic dermatitis.

Poster presenters at AAD 2023 examined the efficacy of 2 different doses of deuruxolitinib for the treatment of alopecia areata.

Poster presenters at AAD 2023 evaluate sociodemographic factors associated with delayed care in patients with skin cancer.

Researchers investigated the safety and efficacy of microencapsulated benzoyl peroxide cream for improving papulopustular rosacea.

A panel of experts throughout Europe have produced an evidence- and consensus-based guideline on therapy recommendations for atopic eczema.

European researchers develop guidance on the clinical assessment of skin burden in patients with psoriatic arthritis.

We speak with prominent alopecia researchers and experts to gain insights into the burden associated with hair loss as well as standard and new treatment options for alopecia.

A summary of recommended diagnosis and management strategies for seborrheic dermatitis is provided.

An international team of researchers summarizes the available medical therapies for melasma and offers suggestions and recommendations for the use of these therapies in clinical practice.

A group of experts convened by the European Society of Contact Dermatitis (ESCD) has published updated clinical practice guidance for the diagnosis, prevention, and treatment of hand eczema.

An expert panel provides recommendations to support comprehensive, personalized, long-term patient management that address all presentations of acne and its current and potential future burden.

A new American Academy of Dermatology (AAD) guideline describes available evidence on comorbidities associated with atopic dermatitis (AD) in adults.

An international consensus establishes dosing recommendations of methotrexate for psoriasis treatment and identifies current knowledge gaps on the topic.

Clinicians review traditional and emerging treatments for atopic dermatitis in the pediatric population, as well as insights from their own experiences.

A team of researchers describe the treatment modalities currently available to manage rosacea, including oral and topical agents, laser and light therapies, as well as skincare.

To explore the different dimensions of acne in the pediatric population, we spoke with clinical dermatologists who are actively involved in the management of acne in children, adolescents, and young adults.

A systematic review and comprehensive critical appraisal of guidelines for psoriasis is performed.

We explore the unmet needs and changes in the treatment landscape for skin infections and the effect of the COVID-19 pandemic on the understanding and management of skin infections, with help from Angela J. Lamb, MD.

New AAD guidelines seek to raise awareness of comorbid disorders in patients with atopic dermatitis among dermatologists and other clinicians.

Experts discuss unmet needs and disparities in dermatology practice and potential initiatives to reduce racial/ethnic disparities in clinical practice.

Several high-priority good practice implementations for ensuring quality assessment and diagnosis of atopic dermatitis (AD) are recommended by a global Atopic Dermatitis (AD) Quality of Care (ADQoC) Initiative.

Disparities in dermatology and the role of ethnic skin centers in addressing these issues are discussed with Angela Lamb, MD.

The efficacy and safety of risankizumab vs ixekizumab in a clinical setting is compared.

Clinical characteristics, disease course, treatments, and health care utilization of the generalized pustular psoriasis (GPP) population is evaluated.

Researchers sought to investigate the predictors of incident MCI and subsequent course of MCI over follow-up and assessed the rates of sustained MCI diagnoses, cognitive normal individuals, and dementia progression.

Treatment with interleukin (IL)-36 receptor inhibitor spesolimab was examined in patients with generalized pustular psoriasis (GPP).

Weight-based dosing strategies and the effect of food intake on absorption and clinical efficacy of sarecycline in patients with acne is examined.

Conclusions from DIPSOC study, which examined the clinical criteria that are of greatest diagnostic value in identifying psoriasis in the pediatric and adolescent population, are reported.